Good Day BIO: Clinical Trials Day and why diversity matters
May 20, 2022
It’s World Clinical Trials Day—so we take a deep dive into why clinical trial diversity matters and what BIO’s doing about it. Plus, three things you need to know—today—about BIO International Convention, which is just three weeks away! (718 words, 3 minutes, 35…
The only newsletter at the intersection of biotech, politics, and policy
May 20, 2022
It’s World Clinical Trials Day—so we take a deep dive into why clinical trial diversity matters and what BIO’s doing about it. Plus, three things you need to know—today—about BIO International Convention, which is just three weeks away! (718 words, 3 minutes, 35 seconds)
Clinical trial diversity is essential for equal access and good medicine
“I think there’s a lot of judgment and paternalism in the healthcare system,” Dr. Lisa Fitzpatrick said in an episode of the I am BIO podcast. “We make decisions about who we think are optimal candidates for participation in research trials, or we make judgments about whether or not we think people can follow through and actually never give them the opportunity to say yes or no or ask for support to be in a clinical trial.”
Why it matters: “By 2040, over half of patients with Alzheimer’s in the U.S. will be Black or Hispanic. Within five years, those cases are predicted to increase by 2% in Black patients, 98% in Latino patients, and 120% in patients of Asian and Pacific Islander ancestry,” said Gerren Wilson, the former head of inclusion strategy and partnerships at Genentech. “We won’t be in a position to provide them the care we aspire to if we don’t change immediately.”
Biotech is making clinical trial diversity a priority—with companies including Amgen, Biogen, and Genentech, to name a few, creating infrastructure necessary to make their trials more inclusive and accessible, as Bio.News details.
Bio.News: Analysis: New study shows hospitals hike cancer drug prices “Hospitals—not manufacturers—often determine what patients and insurers pay for lifesaving cancer drugs,” writes BIO’s Chief Policy Officer John A. Murphy III.
FDA: FDA urges drug manufacturers to develop risk management plans to promote a stronger, resilient drug supply chain “To further assist manufacturers with these requirements, [FDA is] issuing a draft guidance, Risk Management Plans to Mitigate the Potential for Drug Shortages, intended to help with the development, maintenance, and implementation of risk management plans.”
3 things to know about BIO International Convention
We’re just about three weeks away from the convention—whether or not you’ve registered yet, there are three things you need to know today.
3. It’s not too early to get ready for partnering. “The model is simple—you register for the Convention and get access to the partnering system weeks beforehand,” BIO’s Director of Partnering Operations Mackensie Vernetti told Bio.News. You can log on right now and start setting up your profile and scheduling meetings so you’re ready to hit the ground running in San Diego!